Nisa Investment Advisors
KLDO

Nisa Investment Advisors’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Nisa Investment Advisors’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,100
Closed -$9 – 2408
2021
Q1 		$9 Hold
1,100
– – ﹤0.01% 2228
2020
Q4 		$10K Hold
1,100
– – ﹤0.01% 2212
2020
Q3 		$12K Hold
1,100
– – ﹤0.01% 2093
2020
Q2 		$8K Buy
+1,100
New +$7.37K ﹤0.01% 1962

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nisa Investment Advisors's KLDO Position: Q2 2021 in Review

Nisa Investment Advisors sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2021, closing a stake of 1,100 shares — an estimated $9 sold.

Nisa Investment Advisors first reported a position in KLDO in Q2 2020 and held it in 4 quarters. The position peaked at $12K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLDO as of Q2 2021.

  • Nisa Investment Advisors reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,100 Kaleido Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $9.
  • Nisa Investment Advisors first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Nisa Investment Advisors's Kaleido Biosciences, Inc. Common Stock position peaked at $12K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2021.

Based on Nisa Investment Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.